The FDA has granted final approval to Lantheus’s Bravnetsa, the first radiopharmaceutical rated therapeutically equivalent to Novartis’s Lutathera.
Bravnetsa (lutetium Lu 177 dotatate) is approved for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), the same use as Lutathera.
The approval at a glance
- Drug: Bravnetsa (lutetium Lu 177 dotatate)
- Company: Lantheus
- Indication: Adults with SSTR-positive GEP-NETs, including foregut, midgut and hindgut tumours
- Pathway: Abbreviated new drug application (ANDA), the generic route
- Reference product: Lutathera (Novartis)
Why “therapeutically equivalent” matters
The FDA has found Bravnetsa to be bioequivalent and therapeutically equivalent to Lutathera. Lantheus says it is the only lutetium Lu 177 dotatate product with that rating. In practice, that rating allows pharmacies and treatment centres to substitute it for the brand under standard rules.
Competition in radioligand therapy
Bravnetsa is not alone. Curium’s Bexlutry was also recently approved for the same indication. Lutathera now faces competition on two fronts.
Why it matters
- Price pressure. Generic-style competition in radiopharmaceuticals should start to bring down costs for a high-value cancer treatment.
- A maturing field. Radioligand therapy is moving from a single branded product to a competitive market.
- Supply resilience. More suppliers mean less dependence on a single manufacturer.
What it means for the supply chain
Radiopharmaceuticals have one of the toughest supply chains in medicine. Lutetium-177 decays quickly, so doses must be produced, shipped and given to patients within days. Lantheus says it is focused on a “thoughtful launch” and on reliable supply. For hospitals and nuclear medicine centres, a second and third supplier could improve scheduling and reduce the impact of production problems.
The bottom line
Bravnetsa marks the start of real competition in lutetium-based cancer therapy. Watch pricing and how quickly treatment centres switch.
Frequently Asked Questions
What is Bravnetsa? A lutetium Lu 177 dotatate radiopharmaceutical from Lantheus for SSTR-positive GEP-NETs.
How does it compare with Lutathera? The FDA rated it bioequivalent and therapeutically equivalent to Lutathera.
Is it the only competitor to Lutathera? No. Curium’s Bexlutry was also recently approved for the same use.
When will it launch? Lantheus has not given a launch date.
Sources
| Source | Used for |
|---|---|
| OncLive | Approval date, indication, pathway, equivalence and competition |
| CancerNetwork | Approval coverage |
| Targeted Oncology | Approval coverage |
| Fierce Pharma | Regulatory tracker entry |
Additional Resources
| Resource | What you’ll find |
|---|---|
| US Food and Drug Administration (FDA) Orange Book | Therapeutic equivalence ratings |
| Society of Nuclear Medicine and Molecular Imaging (SNMMI) | Radiopharmaceutical practice and supply information |
| Neuroendocrine Tumor Research Foundation | Information on GEP-NETs |
| Lantheus investor relations | Launch and supply updates |
Data note: Pricing and launch timing were not disclosed.